Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.36 |
| ▸ | VHL | P40337 | 2/20 | 0.36 |
| ▸ | ELOC | Q15369 | 1/20 | 0.35 |
| ▸ | ELOB | Q15370 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19505779 | 0.90 | MEN1 (0.42) | MEN1TSHRKMT2APIK3CDHCRTR2 | |
| SCHEMBL19475169 | 0.84 | HCRTR2 (0.35) | MEN1TSHRKMT2AHCRTR2HCRTR1 | |
| SCHEMBL19475398 | 0.79 | NPSR1 (0.38) | MEN1TSHRKMT2AHCRTR2HCRTR1 | |
| SCHEMBL19475396 | 0.79 | NPSR1 (0.38) | MEN1TSHRKMT2AHCRTR2HCRTR1 | |
| SCHEMBL19475315 | 0.78 | KDM4E (0.36) | MEN1TSHRKMT2AHCRTR2HCRTR1 | |
| SCHEMBL19475313 | 0.78 | KDM4E (0.36) | MEN1TSHRKMT2AHCRTR2HCRTR1 | |
| SCHEMBL19505984 | 0.78 | MEN1 (0.35) | MEN1KMT2AHCRTR2HCRTR1 | |
| SCHEMBL19475330 | 0.77 | HTT (0.36) | MEN1TSHRKMT2AHCRTR2HCRTR1 | |
| SCHEMBL19475329 | 0.77 | HTT (0.36) | MEN1TSHRKMT2AHCRTR2HCRTR1 | |
| SCHEMBL11638150 | 0.76 | KDM4E (0.49) | ATMMEN1TSHRKMT2APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647671-B2 | Promysalin analogues and methods of use thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190161444-A1 | Novel Promysalin Analogues and Methods of Use Thereof | Temple University--of the Commonwealth System of Higher Education | 2019-05-30 | — | — | US | disclosed |
| WO-2017184558-A1 | NOVEL PROMYSALIN ANALOGUES AND METHODS OF USE THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647671-B2 | Promysalin analogues and methods of use thereof | CCL11, MAN2A1, PREP | ATM 4356/4885MEN1 443/4885TSHR 4103/4885 |
| US-20190161444-A1 | Novel Promysalin Analogues and Methods of Use Thereof | MASP2, MAN2A1, CCL11 | ATM 4330/4885MEN1 484/4885TSHR 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.